42-0202-80

antibody from Invitrogen Antibodies

Targeting: MS4A1 B1, Bp35, CD20, MS4A2

Provider product page for 42-0202-80

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [4]
Comments [0]
Validations
Immunohistochemistry [1]
Other assay [10]

Submit

Product number: 42-0202-80 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD20 Monoclonal Antibody (L26), eFluor™ 615, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The monoclonal antibody L26 recognizes human CD20, a two transmembrane spanning protein found on precursor and mature B lymphocytes. Expression is lost upon differentiation to plasma cells. The levels of CD20 are critical in evaluating malignant B lymphocytes including Non-Hodgkin's Lymphoma, and Acute B cell, Chronic Lymphocytic and Hairy-Cell Leukemias. CD20 plays a role in B cell differentiation and activation. The structure of the protein shows a small extracellular loop with the carboxy and amino termini in the cytoplasmic compartment. The L26 antibody recognizes an epitope in the cytoplasmic domain and therefore requires permeabilization of the tissue for staining applications. Unlike many anti-CD20 antibodies that recognize the extracellular domain, the epitope recognized by L26 will not be blocked by therapeutic antibodies to CD20, like Rituximab.
Antibody clone number: L26
Concentration: 0.2 mg/mL

MS4A1 protein structure - 42-0202-80 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Development of a multispectral panel for the characterization of GC reactivity. (A) Representative example of Ki67 (magenta), CD20 (cyan), PD-1 (red), Bcl-6 (yellow), CD57 (orange), CD4 (green) and FoxP3 (pink) staining patterns in a tonsillar tissue section (left and right panels) and concomitant B-cell follicle and GC boundary delineations (Extrafollicular CD20lo and Follicular CD20hi/dim; Mantle Zone; MZ: CD20dimKi67lo, Light Zone; LZ: CD20hiKi67lo and Dark Zone; DZ: CD20dim Ki67hi) (middle panel). Circles in lower middle panels denote single FoxP3 events. (B) Histocytometry immunophenotyping gating strategy used for the sequential identification of B cells (CD20+Bcl-6+/- Ki67+/-), Tfh (CD4+PD-1hiBcl-6+/- CD57+/-), and Tfr (CD4+FoxP3+) in tonsillar tissue after nuclear staining based cell segmentation on Imaris and FlowJo analysis. F and EF and GC areas were defined based on the respective staining signals for CD20, Ki67 and CD4 and manually gated on FlowJo to extract frequencies for specific tissue localities. (C) Box plots showing the representative frequencies of B cell and CD4+ T-cell populations (Tfh, Treg) in B-cell follicles (CD20 hi/dim areas) as defined by the expression of Ki67/Bcl-6, PD-1/CD57/Bcl-6 and FoxP3 in tonsillar tissue after application of the GC reactivity pipeline. Each box plot circle represents an individual follicle. Colors represent different phenotypic groups. (D) Box plots showing the relative frequencies of B-cells, CD4 T cells, Tfh a

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Development of a multispectral panel for the assessment of tissue-specific T-cell regulation. (A) Representative example of antibody staining patterns for Helios (pink), CD20 (cyan), CD25 (red), IL-10 (yellow), Ki67 (magenta), CD4 (green) and FoxP3 (purple) in a tonsillar tissue section (left and right panels) and distribution of each marker with respect to the MZ, LZ and DZ (middle panels). Circles (pink/purple) in lower middle panels denote individual Helios (pink) and FoxP3 (purple) events. (B) Immunophenotyping gating strategy used for the identification of Tregs and Tfrs in lymphoid tissues of interest based on the expression and coexpression of the transcription factors FoxP3, Helios, the protein marker CD25 and IL10 in histocytometry. (C) Bar graphs (upper row) and violin plots (lower row) showing the frequencies of Tregs and Tfrs in follicular and extrafollicular areas and frequencies of Tfr subsets in a tonsillar tissue section. Circles in violin plots represent individual follicles whereas colors represent different phenotypic subgroups. Images were acquired at 40x (NA 1.3) with 1% magnification. Scale bars are 50um, 10um (zoomed in details) and 5um (Helios and FoxP3 staining patterns) respectively.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Development of a multispectral panel for the topological examination of CD8 T cells. (A) Representative example of antibody staining patterns for FasL (yellow), Ki67 (magenta), CD20 (cyan), Granzyme B (pink), CD57 (orange), CD4 (green) and the nuclear marker JOPRO-1 (blue) and distribution of each protein marker with respect to the MZ, LZ and DZ (middle panels). Yellow circles in lower middle panels denote individual FasL events. (B) Gating strategy used for the immunophenotyping of various CD8 T cell populations (CD8 hi ; CD8 hi GrzB+, CD8 hi FasL+ and CD8 hi GrzB+ FasL+) in in GC (CD20 dim Ki67 hi ), F (CD20 hi/dim )and EF (CD20 lo ) areas. (C) Box plots and bar graphs showing the relative frequencies of four distinct CD8 T cell populations in EF, F and GC; the frequencies of follicular CD8 hi ; CD8 hi GrzB+, CD8 hi FasL+ and CD8 hi GrzB+ FasL+ in six distinct follicles and (D) proportion of each CD8+ cell subset within each locality (EF, F and GC) as a percentage of total cells. Each circle represents a follicle and each color stands for a distinct subpopulation. Images were acquired at 40x (NA 1.3) with 1% magnification. Scale bars are 100um for all panels displaying an entire follicle), 20um in the middle panel close ups and 5um in the right panel single staining close ups.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Development of a multispectral panel for the evaluation of GC microarchitecture. (A) Representative images showing staining for CD31 (yellow), IgD (red), CD20 (cyan), FDC (green), KI67 (magenta) and Collagen I+IV (orange) in a tonsillar tissue section and individual protein marker distributions with respect to the MZ, LZ and DZ of a B-cell follicle (middle panels). Red dotted square enclosures in lower middle panels denote the areas that are presented magnified in the lower middle panels. (B) Gating strategy used for the sequential positional immunophenotyping of naive B-cells (IgD hi ) in F (CD20 hi/dim ) areas using histocytometry. (C) Box plots showing the areas (um3) occupied by each individual microarchitectural component namely B-cell follicle; CD20 hi/dim; mantle zone: IgD hi , GC (CD20 dim Ki67 hi ) and FDC network (FDC hi ) in eight distinct B cell follicles as measured by surface analysis in the program Imaris as well as the relative areas occupied by Collagen (Collagen I+IVhi) and vascular and lymphatic endothelium (CD31 hi CollagenI+IV hi ) in EF areas, F areas and GCs. Images were acquired at 40x (NA 1.3) with 1% magnification. Scale bars are 100um for all panels displaying an entire follicle), 20um in the middle panel close ups and 5um in the right panel single staining close ups. BEC, Blood Endothelial Cell; LEC, Lymphatic Endothelial Cell.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Development of a multispectral panel for the topological examination of DCs. (A) Representative images showing staining for CLEC9A (yellow), CD20 (cyan), CD11c (orange), CD123 (red), CD8 (pink), CD4 (green), Ki67 (magenta) and JOPRO-1 (blue) in a tonsillar tissue section and the distribution of each protein marker with respect to the MZ, LZ and DZ (middle panels). Red dotted square enclosures in lower middle panels denote the areas that are presented magnified in the lower middle panels. (B) Gating strategy used for the sequential positional immunophenotyping of CD4, CD8, CD20, CD11c+, CD11c+CLEC9A+CD123- and CD11c-CD123+CLEC9A- in GC (CD20 dim Ki67 hi ), F (CD20 hi/dim ) and EF (CD20 lo ) areas using histocytometry. (C) Box graphs and box plots showing the relative frequencies of CD11c+, CD11c+CLEC9A+CD123- and CD11c-CD123+CLEC9A- immune cells in tonsillar tissue as well as in CD20 hi/dim areas (upper panels) and relative frequencies of CD20, CD4, CD8 and CD11c+ immune cells in nine individual follicles. Images were acquired at 40x (NA 1.3) with 1% magnification. Scale bars are 100um for all panels displaying an entire follicle), 20um in the middle panel close ups and 5um in the right panel single staining close ups.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Accumulation of functional monocytes in proximity to follicular areas during SIV infection. ( A ) Representative flow cytometric plots showing the gating scheme for identification of monocyte subsets and pooled data showing the relative frequency of CD14 hi CD16 hi monocytes in LNs from noninfected RMs ( n = 11), chronically infected RMs ( n = 11), and chronically infected AGMs ( n = 5). * P < 0.05, by Mann-Whitney U test. ( B ) Linear regression analysis showing the association between the frequency of LN CD14 hi CD16 hi monocytes and LN total CD8 + T cells. ( C ) Representative confocal images showing the distribution of monocytes (CD163 hi , in red) and granulocytes (MPO hi , in green) in LN tissues from noninfected and acutely and chronically SIV-infected RMs. Two zoomed areas close to the B cell follicle (defined by CD20 and Ki67 expression) from each animal are also shown. Scale bars: 400mum (top two), 200 mum (third row), and 300 mum (lower); enlarged 50 mum; 40 mum (second row, right). Original magnification, x20. ( D ) Pooled data showing CXCL10 production by CD14 hi CD16 hi and CD14 hi CD16 lo monocytes (flow cytometric intracellular staining analysis) after short in vitro stimulation with either IFN-alpha or IFN-gamma. Cells from noninfected ( n = 8) and chronically SIV-infected ( n = 8) RMs were analyzed. * P < 0.05, by Mann-Whitney U test. ( E ) Relative frequency of LN CD14 hi CD16 hi monocytes before and after cART from RMs tr

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Differential protein expression of BCL-2 family members in primary human B cells. ( a ) Western blot analysis for indicated BCL-2 family members in tonsil B cells, fluorescence-activated cell sorting (FACS)-purified as shown in Figure 1a . Data is representative of two (BFL-1, BIK and BIM) to four (BCL-2, MCL-1 and BCL-XL) independent experiments. ( b ) Quantified western blots shown in a corrected for expression of Actin and relative to naive B cells. BFL-1 expression could not be quantified due to the low expression level. Data are average values of three to four different experiments with S.E.M. ( c ) Fluorescence microscopy image of a tonsil section showing MCL-1 protein staining in a CD20 + GC in the tonsil. Scale bar, 100 mu m in overview image (left panel) and 20 mu m in selection (right panel). Images are representative of three individual experiments. Statistics were calculated in relation to Bn cells. * P 0.05, ** P 0.01